Evolus reports Q3 2026 revenue up 13%, reaffirms 2026 and 2028 outlooks
Evolus posted a fourth straight quarter of positive adjusted EBITDA and said it still expects FDA approval of Evolysse Sculpt by year-end 2026.
SEC filing
1 story
Evolus posted a fourth straight quarter of positive adjusted EBITDA and said it still expects FDA approval of Evolysse Sculpt by year-end 2026.
SEC filing